Analyst Julian Harrison from BTIG maintained a Buy rating on Theravance Biopharma and keeping the price target at $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison has given his Buy rating due to a combination of factors surrounding Theravance Biopharma’s promising developments in their Phase 3 CYPRESS trial for ampreloxetine. The trial, which focuses on treating symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), has completed enrollment and is expected to yield results in the first quarter of 2026. The previous Phase 3 Study 0170 showed positive outcomes for ampreloxetine, particularly in its ability to improve symptoms without exacerbating supine hypertension, a significant concern with existing treatments.
Harrison highlights that the CYPRESS trial is designed with input from the FDA, incorporating a longer randomized withdrawal period and utilizing a comprehensive OHSA composite score to better capture the drug’s benefits across various symptoms. This design aims to enhance the differentiation from placebo and increase the likelihood of a pronounced effect. Additionally, the consistency in enrollment criteria between the CYPRESS and previous trials, supported by an external committee of clinical neurologists, strengthens the potential for positive results. These factors, combined with the specific focus on MSA patients who are more likely to respond to norepinephrine-based therapies, underpin Harrison’s optimistic outlook and Buy rating for Theravance Biopharma.
In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $26.00 price target.